Hyloris And Hikma Get Maxigesic IV Approval In US
Launch Of Novel Paracetamol/Ibuprofen Solution For Infusion Is Expected In Early 2024
Hyloris has announced US FDA approval for its Maxigesic IV innovative paracetamol/ibuprofen solution for infusion. The product is expected to launch in the US in early 2024 via marketing partner Hikma, under the name Combogesic IV.
